Tests additionally detect the mutant variants that first appeared within the UK and South Africa
SARS-CoV-2 detection of the Vivalytic exams from Bosch Healthcare Solutions GmbH isn’t affected by the mutations that have been first recognized within the UK and South Africa (VOC 202012/01, B.1.1.7.; 501Y.V2, B.1.351). As the exams detect the virus by amplifying goal sequences inside the viral genetic materials that aren’t influenced by the mutations current within the new strains, it is vitally unlikely that check efficiency will probably be impaired. This applies to the VRI multiplex check developed in collaboration with Randox Laboratories Ltd. in addition to to the SARS-CoV-2 speedy check. The latter is a joint growth with R-Biopharm AG which, as a singleplex speedy check, delivers a outcome on constructive samples in lower than 30 minutes and will also be used for pooling.
Marketing & Communication
+49 (0) 711 811-45 599